REG4 overexpression was associated with poor prognosis and resistance to gemcitabine treatment in one study, suggesting that adjuvant therapies that target reg4 could enhance the usual gemcitabine-based treatment of pancreatic cancer [75,116,117]. This evidence concerns the gene REG4 and familial pancreatic carcinoma.